Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516291 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT04516291: Completed Phase 2 study, sponsored by Pfizer.
NCT04516291 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 286 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04516291, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered subcutaneously (SC) at various doses and regimens in participants with dyslipidemia, defined in this study as participants with elevated non-HDL-C and TG who are receiving a stable dose of a statin. This study is also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia (TRANSLATE-TIMI 70).
Primary Outcome
Fasting was required at least 10 hours before blood sample collection. Baseline was calculated using the average of all values obtained at Screening and on Day 1 prior to dosing.
Interventions
- DRUG Placebo
- DRUG Vupanorsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2021-12-06 |
| Phase | Phase 2 |
What the finished NCT04516291 record still lists
NCT04516291 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04516291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04516291 about?
NCT04516291 is a clinical study titled "A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)". This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered subcutaneously (SC) at various doses and regimens in participants with dyslipidemia...
What is the current status of trial NCT04516291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2020-09-28. Estimated completion is 2021-12-06.
What interventions are being tested in trial NCT04516291?
The interventions under investigation include: Placebo (DRUG), Vupanorsen (DRUG).
Who is sponsoring clinical trial NCT04516291?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04516291's enrollment target sits among peer trials
286 191st of 2000 higher than 1,809 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI